Steven Hanlon
Overview
Explore the profile of Steven Hanlon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabat N, Stampfli A, Hanlon S, Bisagni S, Sladojevich F, Puntener K, et al.
Nat Commun
. 2024 Sep;
15(1):8009.
PMID: 39271668
Chemical modification of DNA is a common strategy to improve the properties of oligonucleotides, particularly for therapeutics and nanotechnology. Existing synthetic methods essentially rely on phosphoramidite chemistry or the polymerization...
2.
Sabat N, Stampfli A, Flamme M, Hanlon S, Bisagni S, Sladojevich F, et al.
Chem Commun (Camb)
. 2023 Nov;
59(98):14547-14550.
PMID: 37987464
Herein, we report the high-yielding solid-phase synthesis of unmodified and chemically modified trinucleotide triphosphates (dNTPs). These synthetic codons can be used for enzymatic DNA synthesis provided their scaffold is stabilized...
3.
Sabat N, Katkevica D, Pajuste K, Flamme M, Stampfli A, Katkevics M, et al.
Front Chem
. 2023 May;
11:1161462.
PMID: 37179777
Enzymatic, XNA synthesis represents an alternative method for the production of long oligonucleotides containing chemical modifications at distinct locations. While such an approach is currently developed for DNA, controlled enzymatic...
4.
Flamme M, Hanlon S, Marzuoli I, Puntener K, Sladojevich F, Hollenstein M
Commun Chem
. 2023 Jan;
5(1):68.
PMID: 36697944
Chemically modified oligonucleotides have advanced as important therapeutic tools as reflected by the recent advent of mRNA vaccines and the FDA-approval of various siRNA and antisense oligonucleotides. These sequences are...
5.
Flamme M, Hanlon S, Iding H, Puentener K, Sladojevich F, Hollenstein M
Bioorg Med Chem Lett
. 2021 Jul;
48:128242.
PMID: 34217829
Therapeutic oligonucleotides require the addition of multiple chemical modifications to the nucleosidic scaffold in order to improve their drug delivery efficiency, cell penetration capacity, biological stability, and pharmacokinetic properties. This...
6.
Hanlon S
Chimia (Aarau)
. 2020 Jun;
74(5):342-344.
PMID: 32482209
Since its inception in 2004, the Swiss Industrial Biocatalysis Consortium (SIBC) has brought together scientists from the Pharma, Fine Chemicals, Agrochemicals and Flavor and Fragrance Industries with the goal of...
7.
Wetzl D, Berrera M, Sandon N, Fishlock D, Ebeling M, Muller M, et al.
Chembiochem
. 2015 Jun;
16(12):1749-56.
PMID: 26044455
Recent investigations on imine reductases (IREDs) have enriched the toolbox of potential catalysts for accessing chiral amines, which are important building blocks for the pharmaceutical industry. Herein, we describe the...
8.
Ceccarelli S, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, et al.
ChemMedChem
. 2007 Nov;
3(1):136-44.
PMID: 17994660
Detailed information on the metabolic fate of lead compounds can be a powerful tool for an informed approach to the stabilization of metabolically labile compounds in the lead optimization phase....